Multiple Sclerosis Therapies Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global Multiple Sclerosis Therapies market garnered revenue around USD 23.98 Billion in 2020 and projected to reach USD 29.02 Billion in 2027, with at a compound annual growth rate (CAGR) 3.4% throughout the estimate period from 2021 to 2027. Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the central nervous system and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual suffering from severe MS experiences speech and movement problems. Multiple sclerosis can be broadly classified into four types, RRMS, SPMS, PPMS, and PRMS. 

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Multiple Sclerosis Therapies market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Multiple Sclerosis Therapies market growth.

The global Multiple Sclerosis Therapies market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

The report provides a comprehensive analysis of the key players operating in the global multiple sclerosis therapies market, which include ABBVIE INC., Bayer AG, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries Ltd.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Type 

·         Immunosuppressants

·         Immunomodulators

By Route Of Administration

·         Oral

·         Injectable

·         Intravenous  

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

 

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Multiple Sclerosis Therapies Market, By Type

7.1.  Multiple Sclerosis Therapies Market, by Type, 2021-2027

7.1.1.    Immunosuppressants

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Immunomodulators

7.1.2.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Multiple Sclerosis Therapies Market, By Route Of Administration

8.1.  Multiple Sclerosis Therapies Market, by Route Of Administration, 2021-2027

8.1.1.    Oral

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Injectable

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    Intravenous

8.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Multiple Sclerosis Therapies Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Type (2016-2027)

9.1.2.    Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Type (2016-2027)

9.1.3.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Type (2016-2027)

9.1.4.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Type (2016-2027)

9.2.2.    Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Type (2016-2027)

9.2.3.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Type (2016-2027)

9.2.4.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Type (2016-2027)

9.2.5.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Type (2016-2027)

9.2.6.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Type (2016-2027)

9.3.2.    Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Type (2016-2027)

9.3.3.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Type (2016-2027)

9.3.4.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Type (2016-2027)

9.3.5.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Type (2016-2027)

9.3.6.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Type (2016-2027)

9.4.2.    Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Type (2016-2027)

9.4.3.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Type (2016-2027)

9.4.4.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Type (2016-2027)

9.4.5.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Type (2016-2027)

9.4.6.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Type (2016-2027)

9.5.2.    Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Type (2016-2027)

9.5.3.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Type (2016-2027)

9.5.4.2.        Market Revenue and Forecast, by Route Of Administration (2016-2027)

Chapter 10.  Company Profiles

10.1.              ABBVIE INC.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Bayer AG

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Biogen

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Bristol-Myers Squibb Company

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              F. Hoffmann-La Roche Ltd.

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Merck KGaA

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Novartis AG

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Pfizer Inc.

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              SANOFI

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Teva Pharmaceutical Industries Ltd.

10.10.1.               Company Overview

10.10.2.               Product Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms\

Choose License Type

Checkout Inquiry Sample